What Synchrony Medical does

Synchrony Medical is a clinical-stage medical device company developing the LibAirty Airway Clearance System, an FDA-cleared, home-use respiratory therapy device for patients with chronic lung diseases including COPD, bronchiectasis, and cystic fibrosis. The system consists of two integrated components: a wearable compression vest that applies targeted chest compressions, and a companion mobile app that coaches patients through controlled breathing exercises inspired by the Autogenic Drainage technique. The proprietary innovation is the synchronization of guided breathing with mechanical compressions, which clinical evidence suggests enables superior mucus clearance (6.9g average sputum vs. 3.6g for standard HFCWO therapy in a 28-patient study) in shorter 20-minute sessions.

The company was founded in 2020 through Edge Medical Ventures' EdgeLabs program in collaboration with pulmonologists at Sheba Medical Center in Israel. It received FDA clearance in July 2025 and launched commercially in the U.S. in October 2025, with U.S. headquarters in Jersey City, New Jersey and R&D operations in Or Yehuda, Israel. The company generates revenue through hardware sales of the LibAirty system, distributed via respiratory clinics, hospitals, and homecare networks using a sales-led, provider-referral go-to-market motion. No public pricing is disclosed. As of early 2026, Synchrony Medical has raised approximately $8.8 million across four funding rounds, with a board including representatives from lead investors Edge Medical Ventures, Broadfin Holdings, and Consensus Business Group.

Name

Synchrony Medical

Legal name

Synchrony Medical

Website

https://synchrony-medical.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Synchrony Medical is a clinical-stage medical device company that develops the FDA-cleared LibAirty Airway Clearance System, a home-use wearable vest and app combination for patients with chronic respiratory diseases such as COPD, bronchiectasis, and cystic fibrosis.

Ownership category

akta.pro rank

Product category

Respiratory Medical Devices

akta.pro primary industry

Chest Physiotherapy & Airway Clearance Devices (PEP, Oscillatory PEP, HFCWO, Cough Assist) (HLAHAGAJ)

akta.pro secondary industries

COPD & Chronic Bronchitis Management (HLAKANAE), Asthma & Airway Disease Specialty Care (HLAKAAAC), Respiratory & Sleep Therapy Equipment (Oxygen, CPAP/BiPAP, Nebulizers) (HSABAKAD)

Keywords

• Airway clearance systems
• Respiratory medical devices
• Home-use therapy
• COPD treatment devices
• Wearable health technology

Headquarters

HQ city

Or Yehuda

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Revenue generated from the sale of the FDA-cleared LibAirty Airway Clearance System, which consists of the wearable vest device and accompanying app. The system is sold to patients with chronic respiratory conditions through healthcare providers, respiratory clinics, hospitals, and homecare networks.
2. At-Home Respiratory Therapy: Daily at-home therapy device for chronic lung disease patients, providing ongoing treatment that reduces hospitalizations and improves respiratory health outcomes.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Synchrony Medical develops and sells the FDA-cleared LibAirty Airway Clearance System, a home-use respiratory therapy device that combines a smartphone breathing-coach app with a wearable compression vest. The system synchronizes controlled breathing (inspired by the Autogenic Drainage technique) with targeted chest compressions to mobilize and clear lung secretions for patients with chronic respiratory conditions such as COPD, bronchiectasis, and cystic fibrosis.

Product overview

Synchrony Medical offers the LibAirty Airway Clearance System as a unified medical device combining the LibAirty Vest (wearable compression device) and the LibAirty App (breathing coach). The system delivers at-home respiratory therapy for chronic lung diseases such as COPD, bronchiectasis, and cystic fibrosis, using a technique inspired by Autogenic Drainage. The device is FDA-cleared and demonstrated superior efficacy in clinical trials, clearing twice as much sputum as conventional therapies in 20-minute sessions.

Differentiator

Problem solved

Functional benefit

Brands

• LibAirty: FDA-cleared Airway Clearance System that synchronizes controlled breathing with chest compressions for patients with chronic lung disease.

Products and services

• LibAirty Airway Clearance System FDA-cleared home-use respiratory therapy system that combines a smartphone breathing-coach app with a wearable compression vest, based on the Autogenic Drainage technique. Designed for patients with chronic lung diseases such as COPD, bronchiectasis, and cystic fibrosis. Clinical studies demonstrate it clears twice as much sputum (6.9g vs 3.6g) as standard HFCWO vest therapy in 20-minute daily sessions, with higher patient satisfaction (4.3/5 vs 3.6/5).

Quantifiable outcome

• Clears twice as much sputum (6.9g average vs 3.6g for standard HFCWO therapy)
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Sheba Medical CentermajorStrategic or Co-development Partner · 18 February 2026The LibAirty system was developed in collaboration with pulmonologists at Sheba Medical Center, one of Israel's leading medical institutions. This clinical collaboration provided medical expertise and validation during the product development process.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Baxter International: Baxter acquired Hill-Rom, which previously acquired Respiratory Technologies, owner of The Vest airway clearance system — the dominant HFCWO device in chronic respiratory care. Direct competitor in airway clearance devices for COPD, bronchiectasis, and cystic fibrosis patients, with far greater commercial reach.
• Electromed: Public company (NYSE: ELMD) that manufactures the SmartVest airway clearance system, a direct HFCWO competitor. Targets the same patient population (bronchiectasis, COPD, cystic fibrosis, neuromuscular) via home-use prescription channels, making it the closest publicly traded comparable to Synchrony Medical.
• International Biophysics Corporation: Manufacturer of the AffloVest, a portable battery-powered HFCWO airway clearance vest. Competes directly with LibAirty in the home-use respiratory therapy market, particularly for patients seeking mobility and ease-of-use advantages.
• Monaghan Medical Corporation: Manufacturer of the Aerobika oscillating positive expiratory pressure (OPEP) device and other airway clearance therapy products. Directly competes with LibAirty in the airway clearance category, though focused on simpler, lower-cost PEP/OPEP devices rather than vest systems.
• RespirTech (a Phillips brand): Former subsidiary of Respiratory Technologies (now under Baxter/Phillips transition), manufacturer of the InCourage airway clearance vest system. Direct HFCWO competitor targeting the same chronic respiratory disease patients via home prescription.

Emerging players

• Dymedso: Manufacturer of the Frequencer V2, an acoustic airway clearance device that uses sound waves to mobilize secretions. Competes in the non-HFCWO airway clearance niche alongside LibAirty's novel breathing-compression approach, targeting similar chronic lung disease patients.
• Belluscura plc: UK-based developer of portable oxygen concentrators and related respiratory devices. While focused on oxygen therapy rather than airway clearance, Belluscura is a comparable early-stage public med-device company commercializing next-generation home respiratory products.

Broad incumbents

• Koninklijke Philips (Philips Respironics): Major respiratory care incumbent offering nebulizers, ventilators, CPAP/BiPAP, and airway clearance products. While not a direct HFCWO vest competitor, Philips' broad respiratory portfolio and established payer relationships make it a relevant comparison and potential strategic acquirer.
• PARI Medical Holding: German respiratory device manufacturer offering nebulizers, PEP systems (PARI O-PEP), and airway clearance products. Comparable to Synchrony in the home-use respiratory therapy space, though PARI is more established globally and broader in scope.
• Vyaire Medical: Global respiratory care company (formerly CareFusion/BD respiratory) offering ventilation, airway clearance, and pulmonary diagnostics products. Operates broadly in the same patient population as Synchrony, though primarily in acute care and hospital settings rather than home-use DME.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synchrony Medical